{"success":true,"data":{"pressRelease":{"id":"157514","rtpr_id":"nBw8Crxn9a-20261001","ticker":"ROPC","exchange":"","all_tickers":["ROPC"],"title":"Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions","author":"Business Wire","published_at":"2026-10-01T06:00:00.490Z","article_body":"Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World\nEffectiveness and Safety Across Major Retinal Conditions\n\n\n * New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust\neffectiveness and durability across previously untreated and treated eyes,\nwith no new safety signals\n\n * Advanced AI-enabled analysis of imaging confirms rapid and meaningful\nanatomical drying supporting Vabysmo as a standard-of-care therapy in routine\nclinical care\n\n * With more than 5,000 patients enrolled, VOYAGER is the largest, prospective,\nnon-interventional real-world dataset evaluating Vabysmo across diverse\nclinical practice settings worldwide\n\nGenentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced\ntoday new data from the VOYAGER study evaluating the effectiveness, durability\nand safety of Vabysmo(®) (faricimab-svoa) in wet age-related macular\ndegeneration (AMD), diabetic macular edema (DME) and macular edema following\nretinal vein occlusion (RVO). Across all study cohorts, results confirm the\nreal-world effectiveness of Vabysmo in line with Phase III trial results, with\nvision gains and robust anatomical improvements in untreated eyes and stable\nor improved vision with improved anatomical outcomes in previously treated\neyes.\n\nIn the wet AMD and DME cohorts of the study, vision and central subfield\nthickness (CST) improved in previously untreated eyes, while vision remained\nstable and CST improved in previously treated eyes, after 12 months of Vabysmo\ntreatment. In RVO, both subtypes of the disease showed improvements in\nefficacy in people treated with Vabysmo. In the central/hemi-RVO cohort,\nvision and CST improved in both previously untreated and treated eyes after\nsix months of Vabysmo therapy. In the branch RVO cohort, vision and CST\nimproved in previously untreated eyes, while vision remained stable and CST\nimproved in previously treated eyes, after six months of Vabysmo treatment.\nThe data are being presented at the EURETINA 2026 Annual Meeting in Vienna,\nAustria.\n\n“These real-world results underscore how the efficacy and safety observed in\nour pivotal Vabysmo studies translate directly into routine clinical practice\nglobally,” said Levi Garraway, M.D., Ph.D., chief medical officer and head\nof Global Product Development. “The sustained visual improvements and\nmeaningful anatomical drying seen in the VOYAGER study reinforce the role of\nVabysmo in helping to address important unmet needs for patients with retinal\nconditions.”\n\n“In daily clinical practice, we manage diverse patient populations with\ncomplex treatment histories who don’t always mirror the strict entry\ncriteria of controlled Phase III trials,” said Professor Robyn Guymer, Chair\nof the VOYAGER Steering Committee and Deputy Director of the Centre for Eye\nResearch Australia. “The latest VOYAGER data give physicians from across the\nworld the confidence that Vabysmo delivers sustained visual gains, meaningful\nanatomical drying, and an established safety profile in everyday practice –\nwhether a patient is starting treatment for the first time or transitioning\nfrom another therapy.”\n\nThe new VOYAGER real-world data in wet AMD, DME and RVO are consistent with\nprevious Phase III study results and demonstrate the effectiveness, durability\nand safety of Vabysmo across diverse global practices. Across all cohorts of\nthe study, the presence of subretinal fluid (SRF) or intraretinal fluid (IRF)\nwas consistently reduced in previously untreated and treated eyes. In the wet\nAMD and DME groups, fewer Vabysmo injections were received during months 7-12\ncompared with months 1-6, suggesting extension of treatment intervals.\n                     Mean change in visual acuity (VA)                            Mean change in central subfield thickness (CST)  Presence of subretinal fluid (SRF)  Presence of intraretinal fluid (IRF)  \n                     \n                                                            \n                                                \n                                   \n                                     \n                     \nEarly Treatment Diabetic Retinopathy Study (ETDRS) letters  \nµm                                              \n% of eyes                          \n% of eyes                            \n Wet AMD (after 12 months of Vabysmo treatment)                                                                                                                                                              \n No prior treatment  +4.6                                                         –110.5                                           72.1→25.3                           48.5→20.6                             \n Previously treated  -0.1                                                         -26.1                                            61.6→37.9                           35.4→25.0                             \n DME (after 12 months of Vabysmo treatment)                                                                                                                                                                  \n No prior treatment  +8.2                                                         -127.8                                           26.5→6.8                            87.3→58.1                             \n Previously treated  +2.7                                                         -71.3                                            22.1→9.3                            80.5→68.1                             \n Branch RVO (after 6 months of Vabysmo treatment)                                                                                                                                                            \n No prior treatment  +10.0                                                        -171.3                                           36.3→11.8                           83.8→50.0                             \n Previously treated  +2.0                                                         -59.0                                            15.9→6.6                            82.6→80.3                             \n Central/hemi-RVO (after 6 months of Vabysmo treatment)                                                                                                                                                      \n No prior treatment  +16.6                                                        -287.4                                           50.7→9.8                            85.7→29.4                             \n Previously treated  +3.9                                                         -63.4                                            14.9→10.3                           89.4→74.4                             \n\n\nIn VOYAGER, the Vabysmo safety profile was generally consistent with that\nestablished in the Phase III studies in wet AMD, DME and RVO.\n\nAbout VOYAGER\n\nVOYAGER is the largest global, prospective, non-interventional real-world\nstudy of Vabysmo (faricimab-svoa). It captures real-world data from 28\ncountries/regions across six continents representing more than 5,000 patients\ntreated for wet age-related macular degeneration (AMD), diabetic macular edema\n(DME) or retinal vein occlusion (RVO). The study leverages state-of-the-art AI\nand deep learning algorithms to evaluate SD-OCT images captured during routine\nclinical practice.\n\nAbout Vabysmo(®) (faricimab-svoa)\n\nVabysmo is the first bispecific antibody approved for the eye. It targets and\ninhibits two signaling pathways linked to a number of vision-threatening\nretinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular\nendothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision\nloss by destabilizing blood vessels, causing new leaky blood vessels to form\nand increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A,\nVabysmo is designed to stabilize blood vessels. Vabysmo is approved in more\nthan 100 countries around the world, including the United States (U.S.),\nJapan, the United Kingdom and the European Union (E.U.) for people with\nneovascular or ‘wet’ age-related macular degeneration and diabetic macular\nedema, and in more than 60 countries, including the U.S., E.U. and Japan, for\npeople with macular edema following retinal vein occlusion (RVO). Review by\nother health authorities is ongoing.\n\nVabysmo U.S. Indications\n\nVabysmo (faricimab-svoa) is a prescription medicine given by injection into\nthe eye, used to treat adults with neovascular (wet) age‑related macular\ndegeneration (AMD), diabetic macular edema (DME) and macular edema following\nretinal vein occlusion (RVO).\n\nImportant Safety Information\n\nContraindications\n\nVabysmo is contraindicated in patients who have an infection in or around\ntheir eye, have active swelling around their eye that may include pain and\nredness, or are allergic to Vabysmo or any of the ingredients in Vabysmo.\n\nWarnings and Precautions\n\n\n * Injections like the one for Vabysmo can cause an eye infection\n(endophthalmitis) or separation of layers of the retina (retinal detachment).\nPatients should seek medical care if they experience increasing eye pain,\nvision loss, sensitivity to light, or redness in the white of the eye.\n\n * Vabysmo may cause a temporary increase in pressure in the eye (intraocular\npressure), which occurs 60 minutes after the injection.\n\n * Although not common, Vabysmo patients have had serious, sometimes fatal,\nproblems related to blood clots, such as heart attacks or strokes\n(thromboembolic events). In clinical studies for wet AMD during the first\nyear, 7 out of 664 patients treated with Vabysmo reported such an event. In\nDME studies from baseline to week 100, 64 out of 1,262 patients treated with\nVabysmo reported such an event. In clinical studies for RVO during 6 months, 7\nout of 641 patients treated with Vabysmo reported such an event.\n\n * Retinal vasculitis and/or retinal vascular occlusion, typically in the\npresence of intraocular inflammation, have been reported with the use of\nVabysmo. Healthcare providers should discontinue treatment with Vabysmo in\npatients who develop these events. Patients should be instructed to report any\nchange in vision without delay.\n\nAdverse Reactions\n\nThe most common adverse reactions (≥5%) reported in patients receiving\nVabysmo were cataract (15%) and blood on the white of the eye (conjunctival\nhemorrhage, 8%). These are not all the possible side effects of Vabysmo.\n\nPregnancy, Lactation, Females and Males of Reproductive Potential\n\n\n * Based on how Vabysmo interacts with your body, there may be a potential risk\nto an unborn baby. Patients should use birth control before their first\ninjection, during their treatment with Vabysmo, and for 3 months after their\nlast dose of Vabysmo.\n\n * It is not known if Vabysmo passes into breast milk. Patients should talk to\ntheir healthcare provider about the best way to feed their baby if they\nreceive Vabysmo.\n\nPatients may report side effects to the FDA at (800) FDA-1088 or\nhttp://www.fda.gov/medwatch\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&index=1&md5=7184737bae6800e832f4d12227e3f843)\n. Patients may also report side effects to Genentech at (888) 835-2555.\n\nPlease see additional Important Safety Information in the full Vabysmo\nPrescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Fvabysmo_prescribing.pdf&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=Prescribing+Information&index=2&md5=07a5fdb18dc8304fbd6ba2b38eea946c)\nor visit https://www.Vabysmo.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vabysmo.com&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=https%3A%2F%2Fwww.Vabysmo.com&index=3&md5=910d608d03d02da67a257ceb05cf1447)\n.\n\nAbout Genentech in Ophthalmology\n\nGenentech is researching and developing new treatments for people living with\na range of eye diseases that cause significant visual impairment and\nblindness, including wet age-related macular degeneration (AMD), diabetic\nmacular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and\nother retinal diseases, including rare and inherited conditions.\n\nAbout Genentech\n\nFounded 50 years ago, Genentech is a leading biotechnology company that\ndiscovers, develops, manufactures and commercializes medicines to treat\npatients with serious and life-threatening medical conditions. The company, a\nmember of the Roche Group, has headquarters in South San Francisco,\nCalifornia. For additional information about the company, please visit\nhttp://www.gene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.gene.com&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=http%3A%2F%2Fwww.gene.com&index=4&md5=a9030de7725dcba6d6bfd0c66d0180f4)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930817201/en/\n(https://www.businesswire.com/news/home/20260930817201/en/)\n\nMedia Contact:\n\nNicole Burkart\n\n(650) 467-6800\n\nAdvocacy Contact:\n\nMeg Harrison\n\n(617) 694-7060\n\nInvestor Contacts:\n\nLoren Kalm\n\n(650) 225-3217\n\nBruno Eschli\n\n+41 61 687 5284\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8Crxn9a-20261001","title":"Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions","author":"Business Wire","ticker":"ROPC","created":"2026-10-01T06:00:00.490Z","tickers":["ROPC"],"exchange":"","article_body":"Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World\nEffectiveness and Safety Across Major Retinal Conditions\n\n\n * New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust\neffectiveness and durability across previously untreated and treated eyes,\nwith no new safety signals\n\n * Advanced AI-enabled analysis of imaging confirms rapid and meaningful\nanatomical drying supporting Vabysmo as a standard-of-care therapy in routine\nclinical care\n\n * With more than 5,000 patients enrolled, VOYAGER is the largest, prospective,\nnon-interventional real-world dataset evaluating Vabysmo across diverse\nclinical practice settings worldwide\n\nGenentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced\ntoday new data from the VOYAGER study evaluating the effectiveness, durability\nand safety of Vabysmo(®) (faricimab-svoa) in wet age-related macular\ndegeneration (AMD), diabetic macular edema (DME) and macular edema following\nretinal vein occlusion (RVO). Across all study cohorts, results confirm the\nreal-world effectiveness of Vabysmo in line with Phase III trial results, with\nvision gains and robust anatomical improvements in untreated eyes and stable\nor improved vision with improved anatomical outcomes in previously treated\neyes.\n\nIn the wet AMD and DME cohorts of the study, vision and central subfield\nthickness (CST) improved in previously untreated eyes, while vision remained\nstable and CST improved in previously treated eyes, after 12 months of Vabysmo\ntreatment. In RVO, both subtypes of the disease showed improvements in\nefficacy in people treated with Vabysmo. In the central/hemi-RVO cohort,\nvision and CST improved in both previously untreated and treated eyes after\nsix months of Vabysmo therapy. In the branch RVO cohort, vision and CST\nimproved in previously untreated eyes, while vision remained stable and CST\nimproved in previously treated eyes, after six months of Vabysmo treatment.\nThe data are being presented at the EURETINA 2026 Annual Meeting in Vienna,\nAustria.\n\n“These real-world results underscore how the efficacy and safety observed in\nour pivotal Vabysmo studies translate directly into routine clinical practice\nglobally,” said Levi Garraway, M.D., Ph.D., chief medical officer and head\nof Global Product Development. “The sustained visual improvements and\nmeaningful anatomical drying seen in the VOYAGER study reinforce the role of\nVabysmo in helping to address important unmet needs for patients with retinal\nconditions.”\n\n“In daily clinical practice, we manage diverse patient populations with\ncomplex treatment histories who don’t always mirror the strict entry\ncriteria of controlled Phase III trials,” said Professor Robyn Guymer, Chair\nof the VOYAGER Steering Committee and Deputy Director of the Centre for Eye\nResearch Australia. “The latest VOYAGER data give physicians from across the\nworld the confidence that Vabysmo delivers sustained visual gains, meaningful\nanatomical drying, and an established safety profile in everyday practice –\nwhether a patient is starting treatment for the first time or transitioning\nfrom another therapy.”\n\nThe new VOYAGER real-world data in wet AMD, DME and RVO are consistent with\nprevious Phase III study results and demonstrate the effectiveness, durability\nand safety of Vabysmo across diverse global practices. Across all cohorts of\nthe study, the presence of subretinal fluid (SRF) or intraretinal fluid (IRF)\nwas consistently reduced in previously untreated and treated eyes. In the wet\nAMD and DME groups, fewer Vabysmo injections were received during months 7-12\ncompared with months 1-6, suggesting extension of treatment intervals.\n                     Mean change in visual acuity (VA)                            Mean change in central subfield thickness (CST)  Presence of subretinal fluid (SRF)  Presence of intraretinal fluid (IRF)  \n                     \n                                                            \n                                                \n                                   \n                                     \n                     \nEarly Treatment Diabetic Retinopathy Study (ETDRS) letters  \nµm                                              \n% of eyes                          \n% of eyes                            \n Wet AMD (after 12 months of Vabysmo treatment)                                                                                                                                                              \n No prior treatment  +4.6                                                         –110.5                                           72.1→25.3                           48.5→20.6                             \n Previously treated  -0.1                                                         -26.1                                            61.6→37.9                           35.4→25.0                             \n DME (after 12 months of Vabysmo treatment)                                                                                                                                                                  \n No prior treatment  +8.2                                                         -127.8                                           26.5→6.8                            87.3→58.1                             \n Previously treated  +2.7                                                         -71.3                                            22.1→9.3                            80.5→68.1                             \n Branch RVO (after 6 months of Vabysmo treatment)                                                                                                                                                            \n No prior treatment  +10.0                                                        -171.3                                           36.3→11.8                           83.8→50.0                             \n Previously treated  +2.0                                                         -59.0                                            15.9→6.6                            82.6→80.3                             \n Central/hemi-RVO (after 6 months of Vabysmo treatment)                                                                                                                                                      \n No prior treatment  +16.6                                                        -287.4                                           50.7→9.8                            85.7→29.4                             \n Previously treated  +3.9                                                         -63.4                                            14.9→10.3                           89.4→74.4                             \n\n\nIn VOYAGER, the Vabysmo safety profile was generally consistent with that\nestablished in the Phase III studies in wet AMD, DME and RVO.\n\nAbout VOYAGER\n\nVOYAGER is the largest global, prospective, non-interventional real-world\nstudy of Vabysmo (faricimab-svoa). It captures real-world data from 28\ncountries/regions across six continents representing more than 5,000 patients\ntreated for wet age-related macular degeneration (AMD), diabetic macular edema\n(DME) or retinal vein occlusion (RVO). The study leverages state-of-the-art AI\nand deep learning algorithms to evaluate SD-OCT images captured during routine\nclinical practice.\n\nAbout Vabysmo(®) (faricimab-svoa)\n\nVabysmo is the first bispecific antibody approved for the eye. It targets and\ninhibits two signaling pathways linked to a number of vision-threatening\nretinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular\nendothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision\nloss by destabilizing blood vessels, causing new leaky blood vessels to form\nand increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A,\nVabysmo is designed to stabilize blood vessels. Vabysmo is approved in more\nthan 100 countries around the world, including the United States (U.S.),\nJapan, the United Kingdom and the European Union (E.U.) for people with\nneovascular or ‘wet’ age-related macular degeneration and diabetic macular\nedema, and in more than 60 countries, including the U.S., E.U. and Japan, for\npeople with macular edema following retinal vein occlusion (RVO). Review by\nother health authorities is ongoing.\n\nVabysmo U.S. Indications\n\nVabysmo (faricimab-svoa) is a prescription medicine given by injection into\nthe eye, used to treat adults with neovascular (wet) age‑related macular\ndegeneration (AMD), diabetic macular edema (DME) and macular edema following\nretinal vein occlusion (RVO).\n\nImportant Safety Information\n\nContraindications\n\nVabysmo is contraindicated in patients who have an infection in or around\ntheir eye, have active swelling around their eye that may include pain and\nredness, or are allergic to Vabysmo or any of the ingredients in Vabysmo.\n\nWarnings and Precautions\n\n\n * Injections like the one for Vabysmo can cause an eye infection\n(endophthalmitis) or separation of layers of the retina (retinal detachment).\nPatients should seek medical care if they experience increasing eye pain,\nvision loss, sensitivity to light, or redness in the white of the eye.\n\n * Vabysmo may cause a temporary increase in pressure in the eye (intraocular\npressure), which occurs 60 minutes after the injection.\n\n * Although not common, Vabysmo patients have had serious, sometimes fatal,\nproblems related to blood clots, such as heart attacks or strokes\n(thromboembolic events). In clinical studies for wet AMD during the first\nyear, 7 out of 664 patients treated with Vabysmo reported such an event. In\nDME studies from baseline to week 100, 64 out of 1,262 patients treated with\nVabysmo reported such an event. In clinical studies for RVO during 6 months, 7\nout of 641 patients treated with Vabysmo reported such an event.\n\n * Retinal vasculitis and/or retinal vascular occlusion, typically in the\npresence of intraocular inflammation, have been reported with the use of\nVabysmo. Healthcare providers should discontinue treatment with Vabysmo in\npatients who develop these events. Patients should be instructed to report any\nchange in vision without delay.\n\nAdverse Reactions\n\nThe most common adverse reactions (≥5%) reported in patients receiving\nVabysmo were cataract (15%) and blood on the white of the eye (conjunctival\nhemorrhage, 8%). These are not all the possible side effects of Vabysmo.\n\nPregnancy, Lactation, Females and Males of Reproductive Potential\n\n\n * Based on how Vabysmo interacts with your body, there may be a potential risk\nto an unborn baby. Patients should use birth control before their first\ninjection, during their treatment with Vabysmo, and for 3 months after their\nlast dose of Vabysmo.\n\n * It is not known if Vabysmo passes into breast milk. Patients should talk to\ntheir healthcare provider about the best way to feed their baby if they\nreceive Vabysmo.\n\nPatients may report side effects to the FDA at (800) FDA-1088 or\nhttp://www.fda.gov/medwatch\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&index=1&md5=7184737bae6800e832f4d12227e3f843)\n. Patients may also report side effects to Genentech at (888) 835-2555.\n\nPlease see additional Important Safety Information in the full Vabysmo\nPrescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Fvabysmo_prescribing.pdf&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=Prescribing+Information&index=2&md5=07a5fdb18dc8304fbd6ba2b38eea946c)\nor visit https://www.Vabysmo.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vabysmo.com&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=https%3A%2F%2Fwww.Vabysmo.com&index=3&md5=910d608d03d02da67a257ceb05cf1447)\n.\n\nAbout Genentech in Ophthalmology\n\nGenentech is researching and developing new treatments for people living with\na range of eye diseases that cause significant visual impairment and\nblindness, including wet age-related macular degeneration (AMD), diabetic\nmacular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and\nother retinal diseases, including rare and inherited conditions.\n\nAbout Genentech\n\nFounded 50 years ago, Genentech is a leading biotechnology company that\ndiscovers, develops, manufactures and commercializes medicines to treat\npatients with serious and life-threatening medical conditions. The company, a\nmember of the Roche Group, has headquarters in South San Francisco,\nCalifornia. For additional information about the company, please visit\nhttp://www.gene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.gene.com&esheet=54613384&newsitemid=20260930817201&lan=en-US&anchor=http%3A%2F%2Fwww.gene.com&index=4&md5=a9030de7725dcba6d6bfd0c66d0180f4)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930817201/en/\n(https://www.businesswire.com/news/home/20260930817201/en/)\n\nMedia Contact:\n\nNicole Burkart\n\n(650) 467-6800\n\nAdvocacy Contact:\n\nMeg Harrison\n\n(617) 694-7060\n\nInvestor Contacts:\n\nLoren Kalm\n\n(650) 225-3217\n\nBruno Eschli\n\n+41 61 687 5284\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-01T06:00:00.797225737Z","server_sent_at_ms":1790834400797},"received_at":"2026-10-01T06:00:00.848Z","source_url":"https://www.businesswire.com/news/home/20260930817201/en/"},"analysis":{"id":"146183","press_release_id":"157514","analysis_json":{"industry":null,"redFlags":[],"eventType":"clinical_trial","narrative":"Genentech presented new VOYAGER real-world data at EURETINA 2026 showing Vabysmo's effectiveness, durability and safety in wet AMD, DME and RVO, consistent with Phase III results and with no new safety signals.\n\nVOYAGER is the largest prospective non-interventional real-world study of Vabysmo, with more than 5,000 patients enrolled across 28 countries/regions.\n\nThe release is authored by Genentech (Roche Group) and does not mention or directly affect the FILER ticker ROPC; treat as low-relevance noise for the filer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Roche/Genentech Vabysmo real-world data strength — no linkage to the FILER; suppress for ROPC feeds."},"keyFigures":{"drugName":"Vabysmo (faricimab-svoa)","phaseOfTrial":"Phase III (pivotal, referenced); VOYAGER real-world non-interventional study","customDimensions":{"voyager_countries":28,"voyager_patients_enrolled":5000}},"quotedText":"These real-world results underscore how the efficacy and safety observed in our pivotal Vabysmo studies translate directly into routine clinical practice globally","namedEntities":{"people":[{"name":"Levi Garraway, M.D., Ph.D.","role":"Chief medical officer and head of Global Product Development, Genentech"},{"name":"Professor Robyn Guymer","role":"Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia"},{"name":"Nicole Burkart","role":"Media contact, Genentech"}],"products":["Vabysmo","faricimab-svoa"],"companies":[{"name":"Genentech","relationship":"author of the release; member of Roche Group"},{"name":"Roche Group","ticker":"RHHBY","relationship":"parent of Genentech"},{"name":"Centre for Eye Research Australia","relationship":"mentioned"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a Genentech (Roche Group) real-world data presentation for Vabysmo at EURETINA; the FILER (ROPC) is not mentioned or implicated in the article. No direct disclosure affecting the filer."},"tickerRelevance":{"others":[{"ticker":"RHHBY","relevance":"parent of Genentech, author of the release"}],"primary":"ROPC"},"globalImportance":25,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"unknown/small-cap filer not referenced in article","eventGravity":"positive real-world data for an approved drug, not a binary event","issuerAuthored":false,"filerMentionedInArticle":false}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Genentech presented new VOYAGER real-world data at EURETINA 2026 showing Vabysmo's effectiveness, durability and safety in wet AMD, DME and RVO, consistent with Phase III results and with no new safety signals.\n\nVOYAGER is the largest prospective non-interventional real-world study of Vabysmo, with more than 5,000 patients enrolled across 28 countries/regions.\n\nThe release is authored by Genentech (Roche Group) and does not mention or directly affect the FILER ticker ROPC; treat as low-relevance noise for the filer.","key_figures":{"drugName":"Vabysmo (faricimab-svoa)","phaseOfTrial":"Phase III (pivotal, referenced); VOYAGER real-world non-interventional study","customDimensions":{"voyager_countries":28,"voyager_patients_enrolled":5000}},"named_entities":{"people":[{"name":"Levi Garraway, M.D., Ph.D.","role":"Chief medical officer and head of Global Product Development, Genentech"},{"name":"Professor Robyn Guymer","role":"Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia"},{"name":"Nicole Burkart","role":"Media contact, Genentech"}],"products":["Vabysmo","faricimab-svoa"],"companies":[{"name":"Genentech","relationship":"author of the release; member of Roche Group"},{"name":"Roche Group","ticker":"RHHBY","relationship":"parent of Genentech"},{"name":"Centre for Eye Research Australia","relationship":"mentioned"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T06:00:13.339Z","global_importance":25,"audience_relevance":10,"importance_components":{"tickerTier":"unknown/small-cap filer not referenced in article","eventGravity":"positive real-world data for an approved drug, not a binary event","issuerAuthored":false,"filerMentionedInArticle":false}},"durationMs":7211,"modelName":"glm-5.3-flashx"}}